Related Experiment Video
Updated: Feb 17, 2026
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Roles of macrophage migration inhibitory factor in polymyositis: Inflammation and regeneration
Yu-Qiong Zou1, Wei-Dong Jin2, Ya-Song Li1
11 Department of Rheumatology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Abstract:
Objective To elucidate the clinical significance of macrophage migration inhibitory factor (MIF) serum concentration in patients with polymyositis. Methods Thirty-six patients with polymyositis were enrolled. Serum samples were obtained and stored to detect MIF and interleukin (IL)-6 using commercially available enzyme-linked immunosorbent assay kits. The relationships between these cytokines and clinical data were analyzed. Results The serum MIF concentration was significantly lower in patients in remission (34.74 ± 17.75) and in healthy controls (38.87 ± 9.30 ng/ml) than that in patients with active polymyositis (50.04 ± 23.84 ng/ml). There were no significant differences between healthy controls and patients in remission. The serum IL-6 concentration in patients with active polymyositis (19.67 ± 7.16 pg/ml) was significantly higher than that in patients in remission (15.81 ± 4.00 pg/ml) and controls (8.14 ± 3.71 pg/ml). The serum IL-6 concentration was negatively correlated with the serum MIF concentration (r = -0.283). No relationship was found between the serum MIF concentration and glucocorticoid dose. The MIF concentration peaked twice during treatment when the creatine kinase concentration was decreasing. Conclusion MIF and IL-6 play important roles in the inflammation associated with polymyositis. MIF might also be involved in the early stage of regeneration in polymyositis. MIF may thus serve as a biomarker of disease activity and outcome.
Insights
Macrophage migration inhibitory factor (MIF) serum levels are lower in polymyositis patients in remission. MIF and IL-6 are key inflammatory markers, with MIF potentially indicating early regeneration and disease activity.
Area of Science:
- Immunology
- Rheumatology
- Biochemistry
Background:
- Polymyositis is an inflammatory myopathy characterized by muscle weakness.
- Understanding the role of specific cytokines in disease pathogenesis is crucial for effective management.
- Macrophage migration inhibitory factor (MIF) and interleukin-6 (IL-6) are implicated in inflammatory processes.
Purpose of the Study:
- To investigate the clinical significance of serum macrophage migration inhibitory factor (MIF) concentrations in polymyositis patients.
- To correlate MIF and IL-6 serum levels with disease activity and treatment outcomes in polymyositis.
Main Methods:
- Serum samples were collected from 36 polymyositis patients and healthy controls.
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify serum MIF and IL-6 levels.
- Statistical analyses were performed to assess the relationship between cytokine concentrations and clinical data.
Main Results:
- Serum MIF concentrations were significantly lower in active polymyositis patients compared to those in remission and healthy controls.
- Serum IL-6 concentrations were elevated in active polymyositis patients, showing a negative correlation with MIF levels.
- MIF levels peaked during treatment concurrent with decreasing creatine kinase, suggesting a role in regeneration.
Conclusions:
- MIF and IL-6 are important in polymyositis inflammation.
- MIF may serve as a biomarker for disease activity and predict outcomes in polymyositis.
- MIF's potential role in early regeneration warrants further investigation.
Related Concept Videos
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...